cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma
Published 3 years ago • 318 plays • Length 4:10Download video MP4
Download video MP3
Similar videos
-
11:43
cartitude-4: cilta-cel vs standard of care pvd or dpd in lenalidomide-refractory multiple myeloma
-
1:45
cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
-
5:42
comparison of outcomes with cilta-cel in cartitude-1 vs rw soc for pts w/ triple-class exposed rrmm
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
5:03
cartitude-2: evaluating car t therapy cilta-cel in multiple myeloma patients who had early relapse
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
5:16
idecabtagene vicleucel in pts with relapsed and refractory multiple myeloma: updated karmma results
-
9:34
neurologic adverse effects in pts with mm treated with cilta-cel in cartitude-2
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
1:35
long-term efficacy and safety of cilta-cel in patients with relapsed/refractory multiple myeloma
-
5:16
rolling submission for cilta-cel to treat relapsed/refractory multiple myeloma
-
4:33
cilta-cel effective in lenalidomide-refractory multiple myeloma
-
10:18
ide-cel; bb2121, a bcma-targeted car t-cell therapy, in patients with rrmm: initial karmma results
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
58:19
sequencing bcma myeloma therapies
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
2:22
treating multiple myeloma with cilta-cel in earlier settings